CHESTER, N.Y.–(BUSINESS WIRE)–Repro Med Systems, Inc. dba KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and easy-to-use specialty infusion solutions that improve quality of life for patients, today announced that the Company will report third quarter 2021 financial results on Wednesday, November 10, 2021. KORU Medical’s management will host a conference call and webcast at 4:30 p.m. ET that day to discuss the financial results and provide a corporate update.
Conference Call and Webcast Details
The conference call can be accessed by dialing (877) 300-8521 for participants in the U.S. or Canada and (412) 317-6026 for international callers, using conference ID 10160951. A live and archived webcast of the event can be accessed via the IR Calendar on the News/Events page of the Investors section of KORU Medical’s website at www.korumedical.com. The archived webcast will be available for six months.
About KORU Medical Systems
KORU Medical Systems develops, manufactures, and commercializes innovative and easy-to-use specialty infusion solutions that improve quality of life for patients around the world. The FREEDOM Syringe Infusion System currently includes the FREEDOM60® and FreedomEdge® Syringe Infusion Drivers, Precision Flow Rate Tubing™ and HIgH-Flo Subcutaneous Safety Needle Sets™. These devices are used for infusions administered in the home and alternate care settings. For more information, please visit www.korumedical.com.
Contacts
Investor Contact:
Greg Chodaczek
347-620-7010
investors@korumedical.com
At 14-months median follow-up in the pivotal trial, 50% of patients achieved a complete response…
Objective response rate of 69.2% observed in heavily pretreated patient population including patients with BTK…
The study met its primary endpoint of overall survival with a 41% reduction in the…
DENVER, CO / ACCESSWIRE / June 15, 2024 / Each year over 120,000 Coloradans are…
REYKJAVIK, Iceland, June 15, 2024 /PRNewswire/ -- In a recent display of global baking talent,…
– ENERGIZE is the First Study to Demonstrate Efficacy of an Oral Treatment for Non-Transfusion-Dependent Alpha-…